4552 — JCR Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- ¥64bn
- ¥109bn
- ¥40bn
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results
Brief: JCR Pharmaceuticals - Received Marketing Authorization In UAE For Izcargo, Therapy For Hunter Syndrome
Jcr Pharmaceuticals Announces Development Plan In Japan For Givinostat For Duchenne Muscular Dystrophy
Table: Jcr Pharmaceuticals -2025/26 group results
Table: Jcr Pharmaceuticals -2025/26 parent results
Brief: JCR Says Acumen Exercises Exclusive Option For Up To Two Alzheimer's Candidates
Table: Jcr Pharmaceuticals - 9-MTH group results
Table: Jcr Pharmaceuticals -Q1 group results
Table: Jcr Pharmaceuticals -2025/26 parent results
Table: Jcr Pharmaceuticals -2025/26 group results
Table: Jcr Pharmaceuticals -2025/26 group forecast
Acumen jumps after equity raise to advance Alzheimer's drug development
Senior Managing Executive Officer Sonoda To Become President And Representative Director Effective April 1
Table: Jcr Pharmaceuticals - 9-MTH group results
Italfarmaco And Jcr Pharmaceuticals Announce Commercialisation Agreement For Givinostat In Japan And Strategic Collaboration In Rare Disease
Table: Jcr Pharmaceuticals - 6-MTH group results